P-319 How coordinated and integrated multidisciplinary work improved the return to intended oncologic treatment in colon cancer

Abstract

Background: Gastric cancer is a complex disease and the third leading cause of cancer deaths worldwide. To date, surgery remains the only curative strategy in locally advanced gastric cancer (LAGC) patients (pt), although the results of the MAGIC trial supported the implementation of a perioperative treatment (ttx) with epirubicincisplatin-5FU (ECF). Since 2019, the FLOT4-AIO trial showed that perioperative 5FUleucovorin-oxaliplatin-docetaxel (FLOT) improved median overall survival (mOS) compared to ECF. We aimed to assess outcome differences in a non-clinical trial scenario in our LAGC cohort, according to multidisciplinary management in a highly specialized gastro-esophageal cancer functional unit (UFEG) integrating different specialists.Methods: From 2012 to 2018, 114 newly diagnosed LAGC pt were referred to our UFEG. Several UFEG specialists at this first consultation evaluated every case, in order to establish a multimodal therapeutic plan. UFEG is comprised of digestive surgeons, medical oncologists, radiation oncologists, nutritionists, advanced practice nurses, radiologists, digestive endoscopists, pathologists, supportive care physicians, and social workers. All demographic, treatment and survival data were extracted retrospectively from available electronic medical records. abstracts Annals of Oncology Volume 31 -Issue S3 -2020 S193